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Abstract
Background: Among Australians aged 50 and over, an estimated 1 in 4 men and 2 in 5 women will experience a
minimal trauma fracture during their remaining lifetime. Effective fracture prevention is hindered by substantial
undertreatment, even of patients who clearly warrant pharmacological therapy. Poor adherence to osteoporosis
treatment is also a leading cause of repeat fractures and hospitalisation. The aim of this study was to identify current
osteoporosis treatment patterns and gaps in practice in Australia, using general practice data, and to explore general
practitioners’ (GPs’) attitudes to osteoporosis treatment and their views on patient factors affecting osteoporosis
management.
Methods: The study was conducted in two phases. Phase 1 was a longitudinal retrospective cohort study which utilised
data from MedicineInsight – a national general practice data program that extracts longitudinal, de-identified patient data
from clinical information systems (CISs) of participating general practices. Phase 2 included semi-structured, in-depth
telephone interviews with a sample of MedicineInsight practice GPs. Data were analysed using an inductive thematic
analysis method informed by the theory of planned behaviour.
Results: A diagnosis of osteoporosis was recorded in 12.4% of patients over the age of 50 years seen in general practice.
Of those diagnosed with osteoporosis, almost a quarter were not prescribed osteoporosis medicines. From 2012 to 17,
there was a progressive increase in the number of denosumab prescriptions, while prescriptions for bisphosphonates and
other osteoporosis medicines decreased. More than 80% of patients who ceased denosumab treatment had no
subsequent bisphosphonate prescription recorded. Interviews with GPs revealed beliefs and attitudes that may have
influenced their intentions towards prescribing and osteoporosis management.
Conclusions: This study suggests that within the Australian general practice setting, osteoporosis is underdiagnosed and
undertreated. In addition, it appears that most patients who ceased denosumab treatment had no record of subsequent
antiresorptive therapy, which would place them at risk of further fractures. The study supports the need for the
development of clinical education programs addressing GP knowledge gaps and attitudes, and the implementation of
specific interventions such as good reminder/recall systems to avoid delays in reviewing and treating patients with
osteoporosis.
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Background
Osteoporosis – a chronic condition characterised by skel-
etal deterioration and an increased risk of fractures – is a
common and costly public health problem [1]. Minimal
trauma fractures (MTFs) are associated with significant
morbidity and mortality [2]. The prevalence of osteopor-
osis increases with age in both men and women [3]. The
2012 Burden of Disease Report [4] estimated that 4.74
million Australians over the age of 50 had osteoporosis or
poor bone health, and this figure was predicted to increase
to 6.2 million by 2022. It is estimated that among Austra-
lians aged 50 and over, 1 in 4 men and 2 in 5 women will
experience a minimal trauma fracture during their
remaining lifetime [3].
Timely diagnosis and appropriate pharmacological man-
agement of osteoporosis have been shown to reduce frac-
ture rates [5]. According to the Royal Australian College
of General Practitioners (RACGP) osteoporosis guidelines,
bisphosphonates and denosumab are first-line medicines
for the prevention of fractures and repeat fractures in pa-
tients with osteoporosis [6]. In Australia, for patients to
receive subsidised medicines to treat osteoporosis, the
condition must have been diagnosed following a MTF or
based on a bone mineral density (BMD) T-score of − 2.5
or less for patients aged 70 years or older [7].
In Australia, general practitioners (GPs) are the most
likely first point of contact for health-related concerns,
including the diagnosis and treatment of osteoporosis
and are the main prescribers of drug therapy for osteo-
porosis [8]. Individuals hospitalised due to fragility frac-
tures are referred to their GPs by hospitals to ensure
continuity of care. Fracture liaison services do operate in
some parts of Australia and their findings and recom-
mendations about osteoporosis treatment are also com-
municated to the patient’s GP [9]. However, it must be
noted that in Australia patients do not register with a
particular general practice and may receive treatment
from any practice they choose to attend.
Despite remarkable advances in our understanding of
the pathogenesis and treatment of osteoporosis, the
disease is still underdiagnosed and undertreated, even in
patients who clearly warrant pharmacological therapy (i.e.
those with incident MTFs) [10, 11]. Failure to prevent re-
peat fracture is one of the largest gaps in the practice of
evidence-based medicine in Australia [1, 12]. Fewer than
20% of patients presenting with MTFs to hospitals or gen-
eral practices are investigated or treated for osteoporosis
[1, 6]. The 2014–15 Australian National Health Survey re-
ported that nearly 35% of patients with a prior diagnosis
of osteoporosis had not consulted a GP or a specialist in
the previous 12months for their condition [13].
Among those who are prescribed medicines, poor ad-
herence to osteoporosis treatment is a leading cause of
repeat fractures and hospitalisation, with patients either
not taking their treatment as prescribed (poor adher-
ence) or discontinuing therapy within six months (lack
of persistence) [14]. Patient concerns about rare side-effects
of osteoporosis medicines and the perception of lack of
clear evidence in support of their long-term efficacy are
commonly reported reasons for low rates of patient adher-
ence to and persistence with osteoporosis treatment [11,
15]. A 2004 retrospective analysis of dispensing data
showed that only 57% of Australians with osteoporosis per-
sisted with bisphosphonate treatment after 12months [16].
The level of adherence to denosumab since its addition in
2010 to the Pharmaceutical Benefits Scheme (PBS), which
lists medicines subsidised by the Australian Government,
remains unknown. Adherence to denosumab is required
for continued reduction of fracture risk, especially in the
light of evidence of multiple vertebral fractures occurring
after stopping denosumab [6, 17, 18].
In view of these concerns, and the lack of information
about current patterns of osteoporosis treatment using
bisphosphonates and denosumab, current levels of treat-
ment cessation in practice and potential barriers to osteo-
porosis treatment in Australia, the aims of this study were:
1. to identify current trends in osteoporosis treatment
patterns within Australian general practice, and
2. to explore GPs’ beliefs about and attitudes to
osteoporosis treatment and their views and
approaches to managing patient factors affecting
osteoporosis management in Australia.
Methods
The study was conducted in two phases:
 PHASE 1: A longitudinal retrospective cohort study
which utilised data from MedicineInsight to achieve
the first aim of the study - to estimate the
prevalence of a recorded diagnosis of osteoporosis in
general practice, and identify treatment patterns for
osteoporosis medicines, including cessation and
switching of treatment modalities.
 PHASE 2: In-depth interviews with a sample of GPs
who work in MedicineInsight practices to achieve
the second aim of the study.
Phase 1
Study design
This was a longitudinal retrospective cohort study using
MedicineInsight data. The study period spanned 1 January
2011 to 31 May 2018. MedicineInsight is an Australian
large-scale national general practice data program devel-
oped and managed by NPS MedicineWise, a not-for-profit
organisation which provides evidence-based education and
information to health professionals and consumers, with
funding support from the Australian Government
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Department of Health [19, 20]. MedicineInsight’s data col-
lection extracts longitudinal, de-identified patient data from
participating practices’ clinical information systems (CISs),
such as Best Practice and Medical Director 3. The Medici-
neInsight program collects data on patient demographics,
practice encounters (not including progress notes), diagno-
ses, prescriptions, pathology tests and referrals. The data-
base comprises records for an open cohort of patients
(between 15 and 20% of the Australian population) from
more than 3300 GPs in 705 recruited general practices
across Australia.
The RACGP National Research and Evaluation Ethics
Committee granted ethics approval for the MedicineIn-
sight program (NREEC 17–017) in December 2017 for
standard operations and uses of the MedicineInsight
database including the ongoing collection of de-
identified data.
Study population
Patients were selected for this study using the process
described in Fig. 1.
Only patients who had a record of attending a Medici-
neInsight practice which met data quality requirements
and who also fulfilled data quality criteria were selected
for inclusion in the study population. MedicineInsight
data quality requirements included that practices had been
established for at least 2 years before the end of the ana-
lysis period and had no interruptions of longer than 2
months in practice data in the 2 years to the end of the
analysis period. Patient data quality criteria included
complete information for defined age, sex, and postcode,
and at least one entry in one of the diagnosis fields (diag-
nosis, reason for encounter, and reason for prescription).
Additionally, to reliably describe treatment patterns and
cessation, patients had to be regularly attending the prac-
tice throughout the study period; this was defined as hav-
ing had at least one clinical encounter per year every year
during the treatment period and at least one encounter in
the pre- and post- enrolment periods.
In order to infer ‘treatment initiation’ and ‘treatment ces-
sation’ in our study population, we applied a 1-year pre-
washout period (1 January 2012 to 31 December 2012)
and 1-year post-washout period (1 January 2017 to 31 De-
cember 2017), during which time patients must have had
no record of prescription of any of the osteoporosis medi-
cines investigated, for inclusion in the study (Fig. 2). This
assumes that patients who had no record of a prescription
for an osteoporosis medicine during the 1-year pre-
washout period had not taken osteoporosis medicines
prior to the study period.
The osteoporosis population was selected from the
study population as described in Fig. 1. We defined pa-
tients with a recorded diagnosis of osteoporosis as those
who had codes (Docle or Pyefinch medical condition
coding) or free text in the fields ‘diagnosis’, ‘reason for en-
counter’ or ‘reason for prescription’ that indicated osteo-
porosis at any time in their medical records. We did not
use BMD results, which are largely unavailable through
the MedicineInsight dataset, even if recorded in the
patient notes. We did not use a record of prescription for
osteoporosis medicines as part of our definition of a diag-
nosis of osteoporosis as some of these medicines can be
also prescribed for other conditions, and because the use
of osteoporosis medicines was one of the outcome vari-
ables of the study. Osteoporosis was defined by including
many specific search terms and expressions (including
spelling variations). Patients who met the above osteopor-
osis population criteria were further analysed for osteo-
porosis treatment patterns (Fig. 1).
Patients were defined as having had a prescription for
osteoporosis medicines if they had at least one record of
a prescription for denosumab, and/or medicines contain-
ing a bisphosphonate and/or ‘other’ osteoporosis medi-
cines, including strontium ranelate, tibolone, raloxifene
or teriparatide (either singly or in combination), during
the treatment period.
Data collection was also limited to medicines for
which a GP used the CIS to print a prescription for a pa-
tient. Only original (i.e. not repeat) prescriptions for
osteoporosis medicines were examined, as this improved
comparison of the number of original denosumab pre-
scriptions (one every 6 months) with the number of ori-
ginal bisphosphonate prescriptions (one original and 5
repeats, covering a 6-month period) during the treat-
ment period. ‘Original prescriptions’ in this context re-
fers only to each individual prescription item, counted
once, whether or not repeat prescriptions were simultan-
eously added to this item. ‘Original prescription’ does
not refer only to the first or initial prescription that a pa-
tient may have received – it is a term used to distinguish
these prescriptions from repeat prescriptions, which
allow the patient to collect their medicine from the
pharmacy without consulting a GP each time.
Statistical methods
Analyses of the data were conducted using SAS version
9.4 (SAS Institute Inc., Cary, NC, USA), including the
use of the SURVEYFREQ procedure. Descriptive statis-
tics, frequencies, percentages (including characteristic-
specific prevalence) and prevalence ratios were used to
describe the cohort of patients and to present the study
outcomes. To indicate the reliability of the estimates of
prevalence and proportion, 95% confidence intervals
(CIs) were calculated (a range of values that should con-
tain the true measure 95% of the time), as were p-values.
The 95% CIs were adjusted for clustering by general
practice site.
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Phase 2
Study design and population
Semi-structured telephone interviews, 45–60min in dur-
ation, were conducted with a sample of GPs working
within MedicineInsight practices. The interview guide was
informed by a literature review and the results of Phase 1
and was developed in consultation with a GP employed by
NPS MedicineWise and an external endocrinologist. The
interview guide included open-ended questions focussing
on exploring GP views about choice of osteoporosis medi-
cines, use of different treatment patterns, and patient
adherence to and cessation of osteoporosis treatment (See
Additional file 1 for interview questions for GPs). The
interview guide was piloted with an external GP to further
improve validity and highlight any ambiguities.
An invitation to participate in the study was sent via
electronic direct mail to GPs working in MedicineInsight
practices who had previously consented to being contacted
by NPS MedicineWise to participate in research studies.
The invitation included links to the participant information
sheet and consent form, which GPs were required to sign
before participating in an interview. Interviews were
Fig. 1 Study population selection process
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conducted by one investigator at a time convenient to GPs.
An incentive in the form of a voucher was provided to par-
ticipating GPs for their time.
The qualitative GP study received ethics approval from
Bellberry Human Research Ethics Committee (HREC
2018–07-533). Written informed consent for publication
was obtained from participating GPs prior to conducting
the interviews.
Data analysis
Interviews were audio-recorded and content was tran-
scribed verbatim. The data were aggregated to prevent
individual GPs or their patients from being identified.
The data were analysed using an inductive thematic ana-
lysis method [21], which allowed the development of
themes from the original data.
We used the theory of planned behaviour (TPB) to help
inform the analysis [22]. In the TPB, three important con-
structs influence the intention of a person (in this study
the GPs) to adopt a given behaviour (osteoporosis man-
agement): attitude, subjective norm, and perceived behav-
ioural control [22, 23]. Each of these constructs is
influenced by a set of beliefs [24]. Intentions are thus af-
fected by an individual’s perception of the potential posi-
tive or negative outcomes of the behaviour and, external
to self, whether society (in this case professional peers and
patients) is likely to approve (or disapprove) of that action
and by an individual’s sense of how much control they
have in a given situation to enact their desired behaviour.
In clinical practice, external control is exerted by patients,
families, and regulation bodies to name but a few.
Two investigators, JE and PN (pharmacists), independently
coded half of the interview transcripts. From this, segments
of text related to the research question were identified and
labelled as initial ‘codes’, which were then grouped under
higher order categories or ‘themes’. Codes and themes were
then compared and refined until consensus was reached be-
tween the two investigators. The refined codes were then
used for the remainder of the transcripts by one investigator,
and the codes and themes were reviewed by the second in-
vestigator to ensure precision of data analysis. Any similar-
ities and differences were discussed and amended by the
two investigators until consensus was reached and a final
thematic framework was generated. Data that did not fit
under existing themes were coded as new codes and in-
cluded as additional themes or subthemes after discussion
with the study team. In line with the study aims above, only
themes specifically related to GP barriers and gaps in osteo-
porosis treatment in Australia are discussed below.
Results
Phase 1
A total of 203,201 patients met the study inclusion criteria
(Table 1). A diagnosis of osteoporosis was recorded for 25,
188 of these patients, giving an overall prevalence of 12.4%
(95% CI 11.7 to 13.0%). Significantly more women (17.6%)
than men (5.3%) had a recorded diagnosis of osteoporosis,
and this proportion increased with age in both genders
Fig. 2 Study timeline, MedicineInsight 2011–2018
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(Table 1). The prevalence of a recorded diagnosis of osteo-
porosis was broadly consistent across quintiles of Socio-
Economic Indexes for Areas (SEIFA). Regarding rurality,
the proportion of patients with a recorded diagnosis of
osteoporosis was lowest in remote areas (6.8%) and high-
est in major cities (13.0%).
Trends in osteoporosis medicine prescribing
The study examined the number of original prescriptions
in each subgroup of osteoporosis medicines – bispho-
sphonates, denosumab and other osteoporosis medicines
– as a proportion of the total number of osteoporosis
medicine prescriptions on record for the study cohort per
calendar year, as well as the changes in the proportion of
osteoporosis medicines prescribed compared to the total
number of all medicines prescribed to the study cohort.
For osteoporosis medicines specifically, there was a
steady increase in the total annual number of prescrip-
tions for osteoporosis medicines, from just under 20,000
in 2012 to nearly 35,000 prescriptions in 2017 in this
study cohort (Fig. 3). This was due to a progressive in-
crease in the number of denosumab prescriptions, while
at the same time prescriptions for both bisphosphonates
and other osteoporosis medicines decreased (Fig. 3). Bis-
phosphonate and denosumab prescriptions together
accounted for more than 85% of all osteoporosis medi-
cine prescriptions over the study period.
Osteoporosis medicine prescriptions for patients
Three-quarters (76.5%) of patients with a recorded diag-
nosis of osteoporosis also had a record of prescription
for osteoporosis medicines (Table 2). These data suggest
Table 1 Patient sociodemographic characteristics and prevalence of a recorded diagnosis of osteoporosis, MedicineInsight 2012–17
CHARACTERISTICS Total patient study
population N = 203,201
Patients with osteoporosis
recorded N = 25,188
Prevalence of recorded
diagnosis of osteoporosis
Number Number Proportion (%) 95% CI
Sex Male 86,221 4589 5.3 4.9–5.7
Female 116,980 20,599 17.6 16.7–18.5
Age (years) 50–59 45,824 1090 2.4 2.2–2.6
60–69 58,306 4033 6.9 6.5–7.3
70–79 58,893 8730 14.8 14.0–15.6
80–89 32,363 8544 26.4 25.1–27.7
≥90 7815 2791 35.7 33.7–37.7
State/Territory Australian Capital Territory 7003 755 10.8 8.7–12.8
New South Wales 76,312 9954 13.0 12.1–14.0
Northern Territory 247 10 4.0 0.9–7.2
Queensland 31,961 4579 14.3 12.7–15.9
South Australia 7962 947 11.9 9.6–14.2
Tasmania 14,144 1335 9.4 8.0–10.8
Victoria 34,903 4181 12.0 10.4–13.6
Western Australia 30,668 3427 11.2 9.4–12.9
Missing 1
Rurality Major city 128,498 16,755 13.0 12.3–13.8
Inner regional 56,654 6722 11.9 10.5–13.2
Outer regional 11,606 1153 9.9 8.3–11.6




1 (least advantaged) 32,553 4184 12.9 11.2–14.5
2 32,372 3993 12.3 11.1–13.5
3 53,017 6084 11.5 10.4–12.5
4 35,848 4647 13.0 11.8–14.2
5 (most advantaged) 48,839 6233 12.8 11.6–13.9
Missing 572
bSocio-Economic Indexes for Areas
Naik-Panvelkar et al. BMC Family Practice           (2020) 21:32 Page 6 of 13
that up to one quarter of patients with a diagnosis of
osteoporosis documented in their files were not pre-
scribed osteoporosis medicines at their regular general
practice over a 5-year period.
Osteoporosis treatment patterns
Given that denosumab and bisphosphonates are the most
commonly prescribed first-line medicines for osteoporosis
in Australia, the analysis of treatment initiation and cessa-
tion was restricted to patients who were prescribed either
denosumab and/or bisphosphonates. Other osteoporosis
medicines were not included in this analysis.
Initiation of osteoporosis medicines
We analysed the initiation of therapy using denosumab or
a bisphosphonate for patients who had a recorded diagno-
sis of osteoporosis and no record of a bisphosphonate or
denosumab prescription in the pre-washout period (n =
18,629) (Fig. 1). During the study period 2013–17, a total
of 12,091 (64.9%) patients were prescribed therapy with
denosumab and/or a bisphosphonate. There were 34.4% of
patients who were started on denosumab but not a bis-
phosphonate, 18.8% who were started on a bisphosphonate
but not denosumab, and 11.7% were prescribed both – a
bisphosphonate and denosumab – at different times dur-
ing the study period. Of the patients who were prescribed
both a bisphosphonate and denosumab, the majority were
prescribed a bisphosphonate before denosumab (82.5%)
(Table 3).
Cessation and substitution of osteoporosis medicines
We also analysed patterns of treatment cessation and/or
substitution in patients who had a recorded diagnosis of
osteoporosis, had at least one recorded prescription of
either denosumab or a bisphosphonate during the first 5
years of the osteoporosis treatment period and had
ceased treatment, based on the date of last prescription,
prior to the post-washout period (Fig. 1). Of the 1122
patients with a recorded diagnosis of osteoporosis, who
had been treated with and subsequently ceased denosu-
mab, 218 (19.4%) patients had a record of a prescription
for a bisphosphonate following denosumab cessation,
therefore 904 (80.6%) patients had no record of a pre-
scription of bisphosphonate either on or after the date of
the last denosumab prescription. Of the 7357 patients
who had ceased bisphosphonate treatment, 4155 (56.5%)
patients had a record of a prescription for denosumab
either on or after the date of the last bisphosphonate
prescription.
Phase 2
Interviews were conducted with 13 GPs from Medici-
neInsight practices in six states in Australia. The eight
Fig. 3 Osteoporosis medicine prescriptions per calendar year, 2012–2017
Table 2 Prescriptions for osteoporosis medicines for patients








No record of osteoporosis medicine 5920 23.5%
aBisphosphonate includes alendronic acid, clodronic acid, ibandronic acid,
pamidronic acid, risedronic acid, zoledronic acid, etidronic acid, tiludronic acid
(either singly or in combination)
bOther includes strontium ranelate, tibolone, raloxifene, and teriparatide
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male and five female GPs had a median of 25 years in
practice. Themes mapped to TPB are shown in Table 4.
GPs subjective norms: gaps in knowledge
Uncertainty about effects of stopping treatment
Most GPs were aware of the quick loss of BMD gains
after stopping denosumab and therefore the need for
denosumab to be administered every 6 months. GPs,
however, expressed uncertainty about when to stop
denosumab, what to do when stopping, the risk of stop-
ping denosumab without an alternative being prescribed,
or what should be prescribed if a patient had previously
had problems with bisphosphonates. As a result of these
concerns, GPs often reported referring their patients to
specialists for advice about stopping, while others chose
not to start denosumab if they thought that the patient
was unlikely to return for a follow-up injection.
Uncertainty about drug holidays
In general, GPs were aware of the concept of drug holi-
days, when patients on longer term medication such as
bisphosphonates have planned breaks from treatment.
Such a holiday was seen as particularly appropriate for
patients who had had a good response to bisphospho-
nates, as indicated by their BMD, and who had not had
a fracture after at least 5 years of medication.
Some GPs expressed uncertainty about whether drug
holidays were an appropriate approach for their patients,
how to undertake drug holidays and what follow-up was
required.
“Well, only because I don’t know how long the studies
have actually been, you know, how long people have
been on these kind of medications. And I understood
that you could have a holiday from the bisphosphonates
and their effect is much more long-lasting. But like I
said, I’ve never felt fully that any – every time I hear a
lecture about osteoporosis or whatever, they never ever
really say exactly how long people should be on things.
Like, it’s pretty vague.” (GP2).
GPs’ attitudes: reluctance to initiate treatment
Perceived lack of urgency of treating osteoporosis
A few GPs expressed the view that, for many patients,
there was no urgency in treating this condition with
‘preventive’ medicines and instead chose to periodically
review and assess their fracture risk.
“Well, none of these preventative things – they don’t
help you, they only really help you if you want to take it
for years. There’s absolutely no rush whatsoever in con-
vincing anything like this. Like blood pressure medication,
nothing is going to happen next week if you don’t take it.”
(GP5).
Medicine-related factors and comorbidities
GPs reported hesitancy in commencing medicines in the
presence of contraindications or comorbidities such as
gastrointestinal disorders, chronic kidney disease, poor
renal function, low calcium and vitamin D levels, and
poor dentition. They were also concerned about poten-
tial side effects of medication.
GPs’ attitudes: perceptions about benefits of treatment
The GPs were not all convinced about the extent of the
effectiveness of osteoporosis medicines and/or their
benefit in certain patient cohorts. Some were particularly
unclear regarding the time of onset and extent of frac-
ture prevention once a medicine was commenced. While
all patients had an ongoing risk of fracture, for some the
benefit of altering this risk was perceived to be minimal.
This uncertainty often influenced the timeliness of GP
prescribing or was the reason for not starting a medicine
in the first place. GPs highlighted the need for more in-
formation to identify patients at highest risk of fracture
who would, therefore, benefit most from treatment.
“I’m a bit reluctant to start the medication unless it’s
really indicated because of the potential side-effects …
mostly the (rare) bone fractures and other indigestion-
type sort of problems. I don’t know if it’s really clear in
my mind that people who are … borderline if they
Table 3 Initiation of bisphosphonates or denosumab in patients
with recorded diagnoses of osteoporosis and no record of













Prescribed bisphosphonate first 1800 9.7%
Prescribed denosumab first 134 0.7%
Prescribed bisphosphonate and
denosumab on the same day
248 1.3%
Table 4 Themes arising from the data based on the TPB
GP behaviour based on
TPB
Themes arising from the data
GPs’ subjective norms • Gaps in knowledge
GPs’ attitudes • Reluctance to start treatment
• Perceptions about benefits of treatment
GPs’ perceived
behavioural control
• Perceived patient factors – lack of knowledge,
low patient adherence
• Organisational factors
• GP approaches to managing patient factors
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benefit from it. It’s only for people I think that are
clearly osteoporotic or having fractures.” (GP11).
GPs’ perceived behavioural control: perceived patient
factors
Poor patient awareness of osteoporosis and its
consequences
GPs considered that most of their patients had low
awareness of osteoporosis and its potential impact,
which they believed to be a strong contributor to patient
non-adherence. This low awareness was particularly at-
tributed to the mainly asymptomatic nature of osteopor-
osis and the absence of its impact on day-to-day life in
its early stages.
“I have a lot of patients would say look, I don’t feel
anything, I’ve got no pain, I’ve got no symptoms, why do
I need any medication?” (GP8).
Patient reluctance to start/continue medicines
GPs perceived that many patients appeared reluctant to
start medicines for reasons including scepticism about
the need for or benefit of the medicine, concerns about
adverse events, medicine administration restrictions and
complexity when taking oral bisphosphonates, cost of
the medicine and polypharmacy.
“If I could convince them to take it I would but there
are some people who just don’t want to take something.
And, because they haven’t actually – particularly the
ones that don’t have or haven’t had obvious fractures,
they don’t feel any ill health, they perceive themselves as
active and so on and they don’t want to take tablets. I
mean you can’t force people to treat something.” (GP2).
GPs also reported that some patients who had com-
menced medicines questioned the need to continue
them, particularly if they were considered to be harmful
or had side-effects. The lack of any tangible benefits of
osteoporosis treatment, particularly in the short term,
was also cited as a barrier to patient adherence. GPs also
mentioned that some patients expressed the desire to
take a break from medicines as they did not believe they
were at high risk of fracture, were sceptical about the ef-
fectiveness of treatment, or had read/heard negative
views about the medicines.
“Again, they just have views that it’s harming them
and it’s because they realise it’s not [for them] … it may
be because they think well, what’s the point, I’ve been
taking it and all this time I haven’t had a fracture, I
should be right now.” (GP9).
GPs’ perceived behavioural control: Organisational factors
Importance of reminder and recall systems to avoid
delaying denosumab
The importance of systems for avoiding delay in adminis-
tering denosumab was highlighted. Nearly all GPs who
regularly prescribed denosumab or zoledronic acid relied
on their reminder and recall systems for ensuring their pa-
tients were followed up for their subsequent doses at the
correct time. However, the absence or deficiencies of such
reminder processes described by some GPs meant that
some of them relied on patients to request a prescription
for denosumab prior to booking a follow-up appointment,
potentially leading to a delay in receiving the medicine.
GPs’ perceived behavioural control: GP approaches to
managing patient factors
Provision of information on osteoporosis and consequences
GPs acknowledged the need to address patients’ poor
awareness of osteoporosis and its consequences though
the provision of information on osteoporosis, its diagno-
sis, consequences such as an increased fracture risk, and
why the patient should consider starting an osteoporosis
medicine. GPs agreed that sharing good information on
osteoporosis is a starting point in the conversation and
helps improve patients’ understanding of osteoporosis
and of the need for medicines. GPs considered prior
fractures, including MTFs, often motivated patients to
persist with their treatment to avoid another fracture.
“I think if they understand what they’re trying to prevent
and how it can impact on their lifestyle, the loss of inde-
pendence is a major motivator to keep the treatment up.”
(GP12).
Patient preference
GPs emphasised the importance of taking patient prefer-
ences into consideration when prescribing and noted the
need to outline the range of osteoporosis medicines
available to patients so they may choose the regimens
that match their lifestyles. Patient involvement in the on-
going review process was also deemed important.
“I let them know about the options they’ve got in
terms of tablets and once a day, once a week, once a
month. Then there’s their injections that are every 6
months and their infusions that are every year. I’d speak
to them and maybe gauge their views on some of those
things.” (GP3).
Discussion
This study aimed to identify current osteoporosis treat-
ment patterns and gaps in practice in Australia, using
general practice data from the MedicineInsight program
and GP interviews. The main findings from the data sug-
gest that, in this population of patients, osteoporosis is
underdiagnosed and undertreated. Of concern is the
possible discontinuation of denosumab without subse-
quent antiresorptive therapy.
In our study, the estimated prevalence of a recorded
diagnosis of osteoporosis in general practice in patients
over the age of 50 was 12%. This proportion increased
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with age and was higher in women (18%) compared to
men (5%), similar to patterns observed in self-reported
national survey data [3]. However, the prevalence of
osteoporosis diagnosis was lower than estimates of
osteoporosis prevalence from Australian population-
based studies, which provide objective data on the true
prevalence of osteoporosis [3, 25]. This could be ex-
plained by a number of factors including under record-
ing of osteoporosis diagnoses or recording of diagnoses
in fields not available to MedicineInsight, the lack of ac-
cess to BMD results and underdiagnosis.
Underdiagnosis of osteoporosis has been reported in the
literature, particularly given the often ‘silent’ nature of this
condition and the likelihood of diagnosing osteoporosis
only when the patient has an MTF [26]. It may also reflect
the under-recognition of osteoporosis in general practice
and/or a lack of salience of the condition [26]. Indeed, GPs
interviewed in our study expressed a lack of urgency in
treating osteoporosis with some not recognising the bene-
fit of treating the condition. A previous study investigating
health provider views around post-menopausal osteopor-
osis reported similar findings, with providers often trivia-
lising post-menopausal osteoporosis, disqualifying it as a
legitimate disease and displaying a lack of urgency in diag-
nosing or treating it [27]. Further, MTFs and complica-
tions were described as infrequent, limited in time and
‘repairable’, and the increased mortality risk was down-
graded as post-menopausal osteoporosis was perceived to
be unlikely [27].
The general practice data in our study showed a steady
increase in the proportion of osteoporosis medicines pre-
scriptions over the study period 2012–17, with a specific in-
crease in the number and proportion of denosumab
prescriptions. Despite the increase in the number of osteo-
porosis prescriptions over the study period, almost a quar-
ter of the patients with a recorded diagnosis of osteoporosis
did not have any record of a prescription for an osteopor-
osis medicine – suggesting potential undertreatment of the
condition within this cohort. It is possible that osteoporosis
treatment may not be indicated in these patients based on
their individual risk factors or may be declined by these
patients [1]. Although we did not investigate risk factors for
osteoporosis or reasons for non-prescription, several other
Australian studies have demonstrated suboptimal rates of
treatment of osteoporosis in primary care, even for patients
with significant risk factors [26, 28–31]. An audit of 10 GPs
in an Australian rural practice, extracting data on patients
with a risk factor for osteoporosis (> 60 years, n = 420) over
a 12-year period, reported that 26% of patients diagnosed
with osteoporosis were not receiving any treatment [28]. A
more recent study using electronic medical records data to
identify rates of osteoporosis in patients aged over 70 years
reported the absence of a recorded current treatment
prescription for 29% of patients with osteoporosis [26].
Further, even the presence of major osteoporotic risk fac-
tors, including prior fractures, did not affect the likelihood
of investigation or treatment of osteoporosis in general
practice [26, 31].
Analysis of the qualitative data using the TPB revealed
GP beliefs and attitudes that may have influenced GPs’
intentions towards osteoporosis management, leading to
the suboptimal treatment rates shown in our study. The
study explored GP beliefs and suggests a lack of clinical
knowledge about ceasing osteoporosis treatment, espe-
cially for denosumab, and about the appropriateness of
drug holidays, especially for bisphosphonates. GPs’ atti-
tudes towards the benefits versus risks of osteoporosis
treatment and the non-urgency of treating the condition
were identified. We explored GPs’ perceived control be-
liefs, including patient factors such as low awareness of
osteoporosis and its impact, as well as, the cost and side
effects of treatment. Some of these factors, especially the
knowledge gaps around therapeutic management of
osteoporosis, have been identified in previous studies
[27, 31]. We hope that the identification of these factors
influencing GP intentions to prescribe will help inform
the development and implementation of specific inter-
ventions to improve the treatment of osteoporosis, such
as clinical education programs addressing GP knowledge
gaps and attitudes in osteoporosis treatment, especially
in the light of relatively newer drugs such as denosumab.
This study demonstrates an increase in the proportion
of denosumab prescriptions during the study period. The
recent evidence demonstrates improved patient preference
for and adherence to 6-monthly subcutaneous denosumab
injections compared to oral bisphosphonates [32, 33]. In
addition, Australian guidelines recommend denosumab as
a first line treatment as well as other treatments [6].
Our study suggests that there is insufficient substitu-
tion with another osteoporosis medicine when ceasing
denosumab in general practice patients. More than 80%
of the patients who had stopped denosumab received no
subsequent prescription for a bisphosphonate, poten-
tially exposing them to rapid bone loss. Cessation of
denosumab (and hence the loss of the drug’s effect on
bone remodelling) leads to rapid bone loss. There have
also been case reports of multiple vertebral fractures oc-
curring shortly after stopping denosumab [17, 34]. A re-
cent post hoc analysis of the denosumab phase 3
randomised trial (FREEDOM) and its extension study
demonstrated a small but significant increase in the risk
of multiple vertebral fractures after cessation of denosumab,
particularly in patients with prevalent vertebral fractures
[35]. All this highlights the need to consider switching to
another osteoporosis therapy if denosumab is discontinued,
to mitigate the potential for rapid bone loss [6, 36].
Similar to denosumab, bisphosphonates were also
stopped without any recorded follow-up treatment being
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substituted for some patients. We cannot tell from the
data the reasons for the failure to continue either medi-
cine, but it is likely that patient non-adherence contributes
to these figures, in that some patients will choose to stop
their medicines without discussion or follow-up. The fac-
tors leading to non-adherence of osteoporosis medicines
are complex [15]. Some of the main patient factors affect-
ing osteoporosis management perceived by interviewed
GPs were poor patient awareness of the potential impact
of osteoporosis, concerns about side effects prior to start-
ing treatment and actual side effects once started, lack of
obvious benefits while on treatment, negative impressions
of medicines from the media or friends/family, and cost. It
is important to check for adherence at every consultation.
Adherence may be improved through patient education,
and pharmacist support as well as shared decision making
when appropriate [37]. Other potential reasons for ceasing
either medicine could be GP preference to cease treat-
ment or lack of efficient recall systems particularly for pa-
tients having 6-monthly denosumab injections.
The interviews indicated that GPs are uncertain about
the effects of stopping denosumab and ways to approach
treatment, particularly if a bisphosphonate had previously
been trialled. This potential uncertainty and lack of know-
ledge around denosumab could be attributed to the fact
that denosumab is a relatively new medicine for many GPs,
compared to bisphosphonates. Education about osteopor-
osis treatment alone is unlikely to be sufficient as we found
other factors that appeared to impact on GP intentions to
prescribe. Such factors influencing adoption and prescrib-
ing of new drugs have been previously highlighted in the lit-
erature including patient factors, drug characteristics,
recommendation from peers and experts, clinical guide-
lines, pharmaceutical marketing and familiarity with the
therapeutic area and knowledge of the drug [38]. We feel
that targeted interventions may help to improve prescribing
and adherence. It is important that general practices use
good reminder/recall systems and consider the sharing of
electronic records across the health system, namely ‘My
Health Record’ which has recently been introduced in
Australia, to improve the overall care and management of
osteoporosis in the community [39].
Strengths and limitations
Patients within the MedicineInsight cohort are broadly
representative of the Australian population in terms of
patient demographics and rates of disease. We have
adopted a mixed methods approach, and our qualitative
findings support the trends in osteoporosis treatment ob-
served using quantitative MedicineInsight data. The latter
cover a substantial segment of the population seen in gen-
eral practice and potentially indicate undertreatment of
osteoporosis. In this context, it is important to note that
the present study analyses treatment initiation only in
patients who already had a recorded diagnosis of osteo-
porosis. As many patients with osteoporosis go undiag-
nosed, this study looks at a subsegment of the total
population of men and women with recorded osteopor-
osis. Based on current guidelines, three-quarters of pa-
tients with a GP-recorded diagnosis of the disease are
being treated with osteoporosis medicines [6]. Our quanti-
tative analyses indicate that the majority of patients who
cease denosumab do not receive maintenance therapy, po-
tentially leaving these patients at risk of bone loss.
This study has limitations. MedicineInsight data depend
on the accuracy and completeness of the data recorded in
the CISs and can vary in quality. Data in CISs are entered
with the primary purpose of managing and providing care
for patients and not specifically for the purpose of research.
This may have led to under-reporting of osteoporosis iden-
tification, depending on GP recording practices. Our defin-
ition of osteoporosis diagnosis was based on commonly
accepted definitions, but there are likely to be variations in
how GPs record a diagnosis of osteoporosis. Due to confi-
dentiality issues, the data extraction could not extend to GP
progress notes, which may have contained further informa-
tion on diagnoses and reasons for prescriptions or encoun-
ters. Prescription counts may have been an overestimate of
actual dispensed prescription counts, as presumably not all
prescriptions and repeats will have been dispensed although
our analyses excluded repeat prescriptions. This study was
unable to retrieve data of patients who receive prescriptions
from GPs at non-MedicineInsight practices, or from spe-
cialists and other services, and was our best approximation
of treatment initiation for our cohort. It must also be noted
that, in Australia, patients do not register with a single gen-
eral practice and are free to visit multiple practices of their
choice. This study assumed that patients who had no rec-
ord of a prescription for an osteoporosis medicine during
the 1-year pre-washout period had not taken osteoporosis
medicine prior to the study. The qualitative study had a
small sample size, which may have affected the trustworthi-
ness of the findings. The qualitative study was designed to
elicit GPs’ perspectives and did not seek to address patient
perspectives directly.
Conclusion
This study suggests that within the Australian general prac-
tice setting, osteoporosis is underdiagnosed and under-
treated. Most patients who had ceased denosumab
treatment had no record of a subsequent prescription for
another anti-resorptive agent to prevent rapid bone loss
usually seen after ceasing denosumab therapy. GP inter-
views indicated GP beliefs and attitudes that may have in-
fluenced their intentions towards osteoporosis prescribing
and management. The study suggests the need for clinical
education programs addressing GP knowledge gaps and at-
titudes in osteoporosis treatment, especially in the light of
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relatively newer drugs such as denosumab. In addition, the
study highlights the need for implementation of specific in-
terventions such as reminder/recall systems and further ex-
ploration of the effects of GP and patient shared decision
making processes.
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